R&D Day Presentation

ADVANCING POWERFUL NEW CLASS OF IMMUNOTHERAPEUTIC ANTIBODIES

R&D Day

13 OCTOBER 2021

© 2021 SAB BIOTHERAPEUTICS, INC.

About this Presentation

This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to the Proposed Business Combination (the "Proposed Business Combination") between Big Cypress Acquisition Corp. ("Big Cypress") and SAB Biotherapeutics, Inc. ("SAB") and for no other purpose. The information contained herein is not all inclusive and none of Big Cypress, SAB or their affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this presentation. Viewers of this presentation should make their own evaluation of SAB and accuracy of the information contained in this presentation and should make such other evaluation as they believe to be appropriate.

Important Information and Where to Find It

Big Cypress intends to file with the SEC a Registration Statement on Form S-4 (the "Registration Statement"), which will include a preliminary prospectus and preliminary proxy statement. The Company will mail a definitive proxy statement/final prospectus and other relevant documents to its stockholders. This communication is not a substitute for the Registration Statement, the definitive proxy statement/final prospectus or any other document that Big Cypress will send to its stockholders in connection with the Proposed Business Combination. Investors and stockholders of Big Cypress are advised to read, when available, the proxy statement/prospectus in connection with Big Cypress' solicitation of proxies for its special meeting of stockholders to be held to approve the Proposed Business Combination (and related matters) because the proxy statement/prospectus will contain important information about the Proposed Business Combination and the parties to the Proposed Business Combination. The definitive proxy statement/final prospectus will be mailed to stockholders of Big Cypress as of a record date to be established for voting on the Proposed Business Combination. Stockholders will also be able to obtain copies of the proxy statement/prospectus, without charge, once available, at the SEC's website www.sec.gov or by directing a request to ir@bigcypressaccorp.com.

Participants in the Solicitation

Big Cypress, SAB and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Big Cypress stockholders in connection with the Proposed Business Combination. Investors and stockholders may obtain more detailed information regarding the names and interests in the Proposed Business Combination of Big Cypress' directors and officers in Big Cypress' filings with the SEC including the Registration Statement to be filed with the SEC by Big Cypress, which will include the proxy statement of Big Cypress for the Proposed Business Combination, and such information and names of SAB's directors and executive officers will also be in the Registration Statement filed with the SEC by Big Cypress, which will include the proxy statement of Big Cypress for the Proposed Business Combination.

Non-Solicitation

This presentation is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Big Cypress, the combined company or SAB Biotherapeutics, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Special Note Regarding Forward-Looking Statements

Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events and other statements that are not historical facts. These statements are based on the current expectations of Big Cypress and SAB's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Big Cypress and SAB. These statements are subject to a number of risks and uncertainties and actual results may differ materially. If any of these risks materialize or if assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Big Cypress and SAB presently do not know or that Big Cypress and SAB currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Big Cypress and SAB's expectations, plans or forecasts of future events and views as of the date of this communication. Big Cypress and SAB anticipate that subsequent events and developments will cause Big Cypress and SAB's assessments to change. However, while Big Cypress and SAB may elect to update these forward-looking statements at some point in the future, Big Cypress and SAB specifically disclaim any obligation to do so. These forward- looking statements should not be relied upon as representing Big Cypress and SAB's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward- looking statements

All trademarks, service marks, and trade names of SAB used herein are trademarks, service marks, or registered trademarks of SAB. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners

© 2021 SAB BIOTHERAPEUTICS, INC.

3

Forward Looking Statements

The material in this presentation has been prepared by SAB Biotherapeutics, Inc. (SAB) and is general background information about SAB's activities current as of the date of this presentation. This information is given in summary form and is not intended to be complete. Information in this presentation, including financial forecasts, should not be

considered advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments and does not take into account any particular investment objectives, financial situation or needs.

This presentation may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to SAB's businesses and operations, market conditions, results of operations and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward-looking statements. SAB does not undertake any obligation to update any information herein for any reason or to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner and the presentation may contain errors or omissions. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside SAB's control. Past performance is not a reliable indication of future performance.

Unless otherwise specified, information is current at the date hereof, unless specifically noted.

© 2021 SAB BIOTHERAPEUTICS, INC.

Innovative DiversitAb™ platform produces a new class of targeted fully-human,highly-potent polyclonal antibodies

© 2021 SAB BIOTHERAPEUTICS, INC.